C-FWMBprecision medicine, cognitive decline, p-Tau 217
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Provide a consumer-accessible Alzheimer's-related blood test for cognition-focused assessment.
Blood-test offering through Neurocode, described in supplied records as using p-Tau 217 testing.
BioSpace record reports BrainScan became available as a consumer Alzheimer's blood test on July 17, 2024.
Address cognitive decline and Alzheimer's disease risk by targeting many underlying contributors rather than a single mechanism.
Precision-medicine protocol described as addressing more than 36 factors that can trigger cognitive decline and using seven complementary strategies to support neuroplasticity.
Used as the foundation for Apollo Health programs including ReCODE, PreCODE, BrainScan/p-Tau 217 testing, health coaching, practitioner training, and nutrition support.
The supplied material links the protocol-based ReCODE approach to reported memory and cognition improvements in a 2025 randomized controlled trial.
Provide nutrition support as part of Apollo Health's cognitive-health and Bredesen Protocol ecosystem.
Dietary/nutrition program referenced as KetoFLEX 12/3 with recipes and related resources.
Listed in Apollo Health site materials among core resources connected to the Bredesen Protocol.
Support prevention of cognitive decline using Apollo Health's Bredesen Protocol-based assessments, testing, coaching, and resources.
Program built around prevention-oriented cognitive-health assessment and protocol-guided lifestyle, testing, and coaching resources.
Listed on Apollo Health's site analysis as one of the company's core Bredesen Protocol-based offerings.
Prevent or reverse cognitive decline and support patients with mild cognitive impairment or Alzheimer's disease through a precision-medicine program based on the Bredesen Protocol.
Precision-medicine intervention addressing multiple cognitive-decline contributors; includes assessments, diet and lifestyle guidance, medications, supplements, coaching, and follow-up tracking.
Reported as significantly improving memory and cognition in a 2025 randomized controlled trial; a 2025 retrospective observational analysis evaluated PHQ-9 depressive-symptom changes in 170 ReCODE participants with mild to moderate Alzheimer's disease.
The supplied material states ReCODE significantly improved memory and cognition in a 2025 randomized controlled trial. The 2025 Brain Sciences analysis found statistically and clinically significant PHQ-9 score reductions after participation, but described the uncontrolled retrospective findings as associative and hypothesis-generating rather than causal.